Cytek Biosciences, Inc. ( (CTKB) ) has released its Q3 earnings. Here is a breakdown of the information Cytek Biosciences, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cytek Biosciences, Inc., a leading cell analysis solutions company, specializes in advancing next-generation cell analysis tools using its patented Full Spectrum Profiling technology. The company operates primarily in the biotechnology sector and offers a comprehensive suite of products and services for research use.
In its third-quarter earnings report for 2025, Cytek Biosciences announced a total revenue of $52.3 million, marking a 2% increase compared to the same period in 2024. The company highlighted its expansion efforts, including the addition of 161 new instruments to its installed base, and the growth in recurring revenue streams.
Key financial metrics revealed a mixed performance, with a GAAP gross profit of $27.6 million, a 5% decrease from the previous year, and an operating loss of $9.2 million compared to a $4.2 million loss in 2024. Despite these challenges, the company saw a 14% year-over-year revenue growth from its biotechnology, pharmaceutical, and clinical research organization customers, and a 19% increase in recurring revenue.
Looking forward, Cytek Biosciences remains focused on expanding its global presence and enhancing profitability. The company reaffirmed its 2025 revenue guidance, projecting a range of $196 million to $205 million, indicating stable growth expectations despite current market conditions.